Polypharmacology – a challenge for current drug design approaches

Autor

DOI:

https://doi.org/10.5604/01.3001.0013.5185

Słowa kluczowe:

G protein-coupled receptors, polypharmacology, serotonin receptors, dopamine receptors, antipsychotic profile, ligands

Abstrakt

Drug design process faces many challenges, and the most important ones are connected with side effects. Finding compounds that possess affinity towards target of interest is relatively simple; however, an approach one disease-one target is now making space for the search of polypharmacological ligands, where activity towards several proteins is considered at one time. Such proteins are not always the target ones, but very often such panels include also anti-targets, interaction with which is not desired, due to the side effects that may occur upon such contact. In the study, we examined ligands of four G protein-coupled receptors, forming antipsychotic profile: dopamine receptor D2, serotonin receptors 5-HT2A, 5-HT2C (anti-target), and 5-HT6. Number of ligands belonging to particular activity groups, as well as the selected compound structures are examined in detail. Also compound similarity between sets of different activity groups is analysed, giving a picture of difficulty of constructing molecular modeling methodologies that can help in the search of compounds with desired activity profile.

Statystyka pobrań

Statystyki pobrań nie są jeszcze dostępne

Hughes JP, Rees SS, Kalindjian SB, Philpott KL: Principles of Early Drug Discovery. British Journal of Pharmacology. 2011; 162: 1239–1249.   Google Scholar

Trist DG: Scientific Process, Pharmacology and Drug Discovery. Current Opinion in Pharmacology. 2011; 11: 528–533.   Google Scholar

Wang J, Li Z, Qiu C, Wang D, Cui Q: The Relationship between Rational Drug Design and Drug Side Effects. Briefings in Bioinformatics. 2012; 13: 377–382.   Google Scholar

Dessalew N, Mikre W: On the Paradigm Shift towards Multitarget Selective Drug Design. Current Computer-Aided Drug Design. 2008; 4: 76–90.   Google Scholar

Katritch V, Cherezov V, Stevens RC: Structure-Function of the G Protein-Coupled Receptor Superfamily. Annual Review of Pharmacology and Toxicology. 2013; 53: 531–556.   Google Scholar

Nichols DE, Nichols CD: Serotonin Receptors. Chemical Reviews. 2008; 108: 1614–1641.   Google Scholar

Berger M, Gray JA, Roth BL: The Expanded Biology of Serotonin. Annual Review of Medicine. 2009; 60: 355–366.   Google Scholar

Kessler RC, Aguilar-Gaxiola S, Alonso J, Chatterji S, Lee S, Ormel J, Ustün TB, Wang PS: The global burden of mental disorders: an update from the WHO World Mental Health (WMH) surveys. Epidemiology and Psychiatric Sciences. 2011; 18: 23–33.   Google Scholar

Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Molecular Psychiatry. 2010; 15: 473–500.   Google Scholar

Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP: ChEMBL: A Large-Scale Bioactivity Database for Drug Discovery. Nucleic Acids Research. 2012; 40: D1100–D1107.   Google Scholar

Warszycki D, Mordalski S, Kristiansen K, Kafel R, Sylte I, Chilmonczyk Z, Bojarski AJ: A Linear Combination of Pharmacophore Hypotheses as a New Tool in Search of New Active Compounds - An Application for 5-HT1A Receptor Ligands. PLoS One. 2013; 8: e84510. 12. InstantJChem Version 15.3.30.0, 2015, Licensed by ChemAxon; www.chemaxon.com (accessed September 203 2019).   Google Scholar

http://bioinformatics.psb.ugent.be/publications/.   Google Scholar

Wang S, Che T, Levit A, Shoichet BK, Wacker D, Roth BL. Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone. Nature. 2018; 555: 269–273.   Google Scholar

Kimura TK, Asada H, Inoue A, Kadji FMN, Im D, Mori C, Arakawa T, Hirata K, Nomura N, Aoki J, Iwata S, Shimamura T. Structures of the 5-HT2A receptor in complex with the antipsychotics risperidone and zotepin. Nature Structural & Molecular Biology. 2019; 26: 121–128.   Google Scholar

Schrödinger Release 2019-3: LigPrep, Schrödinger, LLC, New York, NY, 2019   Google Scholar

Schrödinger Release 2019-3: Glide, Schrödinger, LLC, New York, NY, 2019   Google Scholar

Pándy-Szekeres G, Munk C, Tsonkov TM, Mordalski S, Harpsøe K, Hauser AS, Bojarski AJ, Gloriam DE. GPCRdb in 2018: adding GPCR structure models and ligands. Nucleic Acids Research. 2017; D1: D440–D446.   Google Scholar

The PyMOL Molecular Graphics System, Version 1.2r3pre, Schrödinger, LLC.   Google Scholar

Rogers D, Hahn M. Extended-Connectivity Fingerprints: Journal of Chemical Information and Modeling. 2010; 50: 742–754.   Google Scholar

Bajusz D, Racz A, Heberger K: Why is Tanimoto index an appropriate choice for fingerprint-based similarity calculations? Journal of Cheminformatics. 2015; 7: 20.   Google Scholar

Comparison of docking poses of CHEMBL576756 (magenta) and co-crystallized risperidone (yellow) for a) 5HT2A, and b) D2 receptors. Picture generated in Pymol

Opublikowane

2019-09-30

Jak cytować

Podlewska, S., & Kurczab, R. (2019). Polypharmacology – a challenge for current drug design approaches. Science, Technology and Innovation, 6(3), 19–23. https://doi.org/10.5604/01.3001.0013.5185

Numer

Dział

Artykuły oryginalne